



**MANIFESTATIONS AND PATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
IN NEONATES AND ADULTS - A COMPREHENSIVE REVIEW**

Angelo Soukovelos*

9357 W Monte Lindo, Peoria, Arizona, USA.

*Corresponding Author: Angelo Soukovelos

9357 W Monte Lindo, Peoria, Arizona, USA.

Article Received on 24/12/2020

Article Revised on 14/01/2021

Article Accepted on 04/02/2021

ABSTRACT

Systemic lupus erythematosus (SLE) is a chronic and diversified autoimmune inflammatory disease that can affect any part of the body. SLE is an etiological condition that has many attributes and symptoms that are indeterminate. In recent years, interest in the disease has been stimulated and, as a result of improved screening methods, the number of known cases has risen dramatically. It is clear that we can no longer contend that this is an uncommon illness. The bulk of SLE pathology is associated with multi-tissue deposits of immune complexes, which can lead to supplementation and other inflammatory mediators. The signs range from person to person and can be mild, moderate or extremely extreme in adults as well as in neonates, depending on the part of the body that is affected.

INTRODUCTION

Neonatal lupus is a rare autoimmune disease that mostly presents as skin lupus lesions and/or congenital heart block lesions. The Ro/La family's maternal autoantibodies are present almost everywhere, but hardly 1% of women with such autoantibodies have lupus-induced newborns. Newborn lupus skin lesions may occur at birth, but in the first few weeks of life, they are most likely to develop. Lesions on the face and scalp are often the most noticeable during marked peripheral distribution. In a couple of weeks or months, without weeping, the lesions tend to recover. The most common form of the heart block is neonatal lupus. A obstruction of the heart usually starts in the uterus in the second or third trimester. In certain examples, in the first or second year, a heart block starts as a block and grows into a block in the third year. The entire heart block becomes permanently noticeable after it has been formed. In certain situations, of full heart block, cardiomyopathy exists. Dilated cardiomyopathy has been identified at birth in most cases, but it has been delayed. There have been many occurrences of endocardial fibroelastosis in the absence of congenital heart block. In about 10 percent of cases, hepatobiliary illnesses occur. Three forms of liver disease have been identified: liver dysfunction at birth or in the uterus, intermittent conjunctival hyperbilirubinemia in infants, or a temporary rise in infant transplantation. In about 10 percent of cases, thrombocytopenia, neutropenia, or anemia are responsible for the hematological condition. It is normal for children with neonatal lupus not to be totally sick, but to only damage one or two organ systems (UpToDate, n.d.).

The diagnosis is mainly based on the identification of Ro and/or La or, in some cases, the U1 ribosomal protein for maternal fissures and autoantibodies. While there has been no final determination of pathogenicity, the collection of data, including findings from animal models, indicates that the pathogenicity of the disease is consistent with anthropogenesis itself.

Prevention measures, early diagnosis and treatment of existing diseases, especially with the use of systemic corticosteroids, are involved in the treatment. The right care needs to be there as well. The long-term prognosis for children with neonatal lupus is still being studied, although a number of children with neonatal lupus have acquired autoimmune disorders later in life. About half of mothers are asymptomatic until pregnancy, although certain women display symptoms of autoimmune disorder ("Lupus Erythematosus in Newborns: Clinical Findings and Pathogenesis," 2004).

Systemic lupus erythematosus (SLE) is an autoimmune condition that is chronic and mysterious that can affect nearly every organ throughout the body. Immunological defects, particularly the production of a continuum of anti-nuclear antibodies, are an important characteristic of the disorder. Patients' health characteristics vary from mild involvement of the joints and skin to the risk of involvement of the kidney, hematologist or central nervous system. A diagnosis challenge for the clinician is the absence of SLE variability and the exclusion of pathological functions or exams. There may be bacterial, infectious or hematological conditions in people with some clinical characteristics of SLE that cause their condition worse. On the basis of clinical and laboratory

results, SLE is typically graded without omitting possible diagnosis. In the absence of SLE diagnosis criteria, SLE classification guidelines are also used as a reference for physicians in order to define some of the primary clinical diagnostic functions. In order to demonstrate the possibility of SLE, which is closely associated with certain antibodies (e.g. double-stranded anti-DNA [anti-DDNA] and anti-Smith [anti-Sm]), serological observations are significant (Nakamura et al., 2007).

Research question

What are the clinical manifestations and pathogenesis of systemic Lupus Erythematosus in adults as well as neonates?

Literature review

Pathogenesis of SLE

Anti-Ro, also known as anti-SSA, are the autoantibodies originally identified with NLE. Numerous specifications of auto cars can survive with sera containing anti-Ro. These include antibodies against the initially identified 60 KDa Ro protein, antibodies against a non-homologous protein called 52 KDa Ro and antibodies against the La protein (SSB). Using Ouchterlony tests, Western Blot and ELISA, a systematic analysis that examined the properties of anti-Ro-binding autoantibodies in 20 mother-sera NLE antibodies against 60 KDa Ro in all 20, found antibodies in against 52 KDa Ro in 18 and Antibodies to La in 9 (Lela A. Lee, 2005).

Other features of NLE-related autoantibodies include calreticulin antibodies, 57 KDa antigen, 75 KDa phosphoprotein, alpha-fodrin, neonatal M1 acetylcholine receptor core M1, and in some cases Isolated U1RNP. Ouchterlony assays (immunodiffusion tests) for Ro and La antibodies are the most valuable and clinically important serological test.

Autoantibody and anatomy

The definition of autoantibody stimulation of NLE is right. In the NLE serum, they are still present and are not random, but belong to those specificities found in the Ro family. The activity of NLE disease occurs when maternal autoantibodies are present in the bloodstream of the baby and are affected at the moment or period when the baby is completely metabolized by maternal autoantibodies. Analysis of the accumulation of antibodies in human tissues reveals that anti-Ro antibodies are found in organs that are weakened and untouched. This may not be surprising, considering that Ro and La proteins are usually present in all organs. This does not, however, justify why the NLE comprises the nucleus, the blood, and certain other elements, but does not include certain other organs (Lela A. Lee, 2005).

The Skin in NLE

NLE skin lesions typically grow within a couple of days to a couple of weeks after birth, but some cases have been identified at birth. Lesions are most likely to occur on the face and scalp, but on the extremities and torso,

including the diaper section, they may also appear.

Typically, anatomy consists of an erythema annulare with high red boundaries with central clearance, but may include smooth scale or crustal lesions. The lesion histology is similar to that of adult sub-acute skin lupus with keratinocyte death and superficial mononuclear cell invasion, but with little or no follicular obstruction or scarring. Active disease resolution happens within weeks or months, and deterioration can continue for months or years and can occur with chronic telangiectasia (Lela A. Lee, 1990).

In a study at the University of Colorado, the incidence of SLE (14 females, 4 males) and the frequent occurrence of 'owl eye' periorbital lesions were found in 18 cases of NLE. Photosensitivity was observed in 12 cases and characteristics in telangiectasia of congenital cutis were observed in 4 cases. For four girls, the remaining telangiectasias were present.

Significantly, the diagnosis of NLE was only accepted after dermatological consultation in 17 of the 18 cases (L.A. Lee, 1993).

In NLE, only one organ is commonly confirmed as a compromise and, thus, the skin was obviously the only organ affected in 12 out of 18 cases. Two cases of skin and heart block disorders have been reported; three cases of skin lesions, hepatotherapy and thrombocytopenia; and one case of skin cancer, heart block and thrombocytopenia. Children with NLE skin lesions that have cardiac failure tend to be almost as likely to develop hepatotherapy or hematology, while heart block is the most illustrated NLE result (Izmirly et al., 2012).

NLE of cardiac

A complete congenital (third-stage) (CHB) heart block is NLE cardiac dysfunction. CHB starts in the second or third trimester, nearly in the uterus. Next, a minor move is periodically found in the block, and will proceed into the third step. The findings of the autopsy revealed that fibrosis and calcification had been replaced by the atrioventricular node region. While this outcome does not suggest heart disease in living children, ganglion fibrosis replacement means that CHB is nearly always permanent in living children (Dhaher et al., 1997).

Surprisingly, the sluggish heart rate is clarified by most children with HC and they do not need care. Nevertheless, others involve the implantation of speedometers. In certain cases, in addition to the abnormality of the conduction, cardiomyopathy takes place. To repair cardiac failure in children with serious heart muscle damage, it would not be possible to correct the heart rhythm with a velocity meter, and the outcome is often fatal. Many cases of significant damage to the heart muscle occur at or immediately after birth, but cases of cardiomyopathy occur a few months after birth, indicating the need to track children with NLE regularly

and closely. (Derksen & # 38; Meilof, 1992)

There have been 113 cases of cardiac NLE identified by the registry. The estimates of the male and the female were nearly similar. In the second or early third trimester, heart block was commonly found, with an estimated gestational age of 23 weeks after diagnosis. 63 percent of kids and only 20 percent died from heart failure.

Hepatobiliary disease

Nearly all reports of NLE-related hepatitis have resulted in children with heart or skin damage, and a history of hepatitis has been identified as an isolated outcome. In reviewing the enrollment data, the following types of hepatotherapeutic activity were identified:

Liver damage that develops in the uterus or shortly after birth and is also associated with an iron storage disorder in newborns or a pathological phenotype of haemochromatosis in newborns;

- Acute conjunctival hyperbilirubinemia in the first few weeks of life; and
- Late increases in aminotransferases.

Approximately 10% of patients admitted to the registry showed evidence of hepatotherapy surgery. It is also possible that the number of untreated patients is actually higher and the majority of cases have not been tested for liver enzyme documentation (D'Cruz et al., 2007).

NLE Hematology

In certain cases of NLE, thrombocytopenia has been reported and can occur in up to 10 per cent of cases of cardiac or isolated NLE. It is typically arbitrary and clinically benign, but there is at least one instance of gastrointestinal bleeding associated with it.

Neutropenia has rarely been recorded in NLE, but has occurred in 5 out of 57 NLE isolated infants reported. A hallmark of NLE was some lymphopenia that was reported to interfere with anti-Ro autoantibodies in adults. There have been reports of occasional anemia, which in some cases is characterized by hemolytic anemia (Cojocar et al., 2011).

Pathogenesis in adults by SLE

In SLE pathogenesis, pathological endogenous immune responses play an important role and contribute to tissue damage via the release of inflammatory cytokines and the abnormal activation of autoimmune T and B cells, contributing to the development of pathogens and end organ autoantibodies. Loss. Accident. In order to directly activate autogenous lymphocytes, self- antigenic nucleic acids and their binding proteins are necessary. Complex autoantigens also have their autoantibodies directly connected to stimulating native immune cells by Fc-mediated complex absorption (FcR) (or, in the case of autoimmune B cells, original autoantigens as part of the B-cell antigen receptor) where Toll-like intracellular antigens impact the portion of the nucleic acid of these

complexes at the endosomal t receptor (Choi et al., 2012)

Via activating B and T cells, dendritic cells (DCs) play a key role in adaptive immunity in the hope that they will be similarly important in activating autoimmune T and B cells. Their particular position in autoimmunity, however, and the effect of their selective subgroups on autoimmune lymphocyte activation are still unclear. By adding the highest degree of commonly used residues to a model of DC depletion (toxin CD11c-diphtheria A; CD11c-DTA). This concern with the lupus model has been resolved by recent studies. This mouse presented a rare opportunity to research the normal onset and development of the disease in the absence of DC in animals vulnerable to lupus, indicating that the latter is important for the extent of self-immunity regulation in DC-deficient mice of spontaneously occurring systems. It is less severe than intact DC controls displaying illness. In order to increase autoantibody production, T lymphocytes and plasma blasts rely on DCs in particular, highlighting their previously unrecognized role in stimulating extra follicular humoral responses (EF) in SLE (Choi et al., 2012).

Previous studies by the same and other groups have shown that EF sites in murine lupus are necessary for the continuous activation of short-lived plasma blasts and for the development of autoantibodies (more on this later; see SLE adaptive immunity), B-cell stimulated autoimmune receptor (BCR) and auto antigenic lupus receptor TLR disturbances. Although the role of EF responses in human SLE stimulation is uncertain, largely due to the general lack of access to lymphoid tissues, evidence of a significant number of circulating plasma lesions in patients with active SLE implies that this is the solution. Maybe. Maybe. In view of the role of BAFF in the survival of B cells with myeloid cells that are potentially good producers of this and other soluble and dependent factors, the promotion of plasma explosion activity at the EF sites by DC is advantageous. Contact which supports the maturity of B-cells (Cervera et al., 2009).

DISCUSSION

In patients with SLE, some systemic symptoms may occur. Fever, malaise, arthralgia, myalgia, migraine, and lack of appetite and weight are typical symptoms. In recent or chronic incidents of active SLE, nonspecific fatigue, fever, arthralgia, and weight gain are the most frequent symptoms. Fatigue, which is the most frequent constitutional symptom associated with SLE, can be due to aggressive SLE, drugs, dietary behaviors, mood disturbances, or accompanying fibromyalgia. Furthermore, in combination with other clinical and experimental markers, extreme SLE fatigue occurs. Fever can also have a variety of causes, including violent SLE, inflammation, and opioid fever, with another prominent but unspecific symptom of SLE becoming the most common. A thorough background research may assist them in identifying them. In patients with active

SLE, loss of weight may occur. Corticosteroid treatment or aggressive conditions such as nephrotic hydrops syndrome may also result in weight gain. Other autoimmune conditions, respiratory diseases, endocrine disorders, persistent exhaustion and fibromyalgia may be associated with these signs (Cervera et al., 2009).

Manifestations of musculoskeletal organs

There is extensive musculoskeletal involvement in patients with SLE. People typically visit a specialist for joint pain, which, while there is no chance of joint pain, usually involves the small joints of the arm and the elbow. One of the most common causes of initial clinical diagnosis for patients with SLE is knee pain. Arthralgia, inflammation, osteonecrosis (vascular bone necrosis) and myopathy are the primary manifestations. In about 95% of patients with SLE, arthritis and asthma are known. These signs may be misdiagnosed with some form of inflammatory arthritis, and it can take months to diagnose it, or even years. Little joints in the palms of the hands, wrists, and knees may be associated with arthritis, myalgia, and overt arthritis. Swelling, as well as rheumatoid arthritis, can be asymmetrical and disproportionate of arthritis or SLE. SLE and migraine arthritis are typically arthritis, and within minutes, morning stiffness is normally tested. SLE arthritis is commonly considered non-deformity. In 8% of patients with SLE, antibodies expressing the anti-citrulline peptide (the major anti-homologue) were present. Osteoporosis, which often takes place with glucocorticoid treatment, may increase the risk of fractures. Myositis is present in all patients with SLE, and can be detected by biopsy (Choi et al., 2012).

The manifestations and signs of dermatology

The first lupus identified was a dermatological condition. In order to make a potential diagnosis of lupus, four diagnostic criteria and more guidelines can be found for SLE skin signs. A rash from malaria is the first, then across the cheeks and on the bridge of the nose is an erythematous rash. It takes a couple of days to a couple of weeks and is rarely barefoot or bothersome. The second aspect is photosensitivity, which can be achieved in people who are asked if, following exposure to the sun, they have an irregular rash or deteriorating symptoms. A disc-shaped rash may be the third trait. In areas exposed to light but close to plaque, disc-shaped lesions with healthy plugs and scars often form (Cojocaru et al., 2011).

Neuropsychiatry

In 25 to 75 percent of cases, neurological signs of lupus are observed, and may control all facets of the nervous system. The study found that in patients with neurological symptoms, the number of elevated anti-APL antibodies is about twice as high as in patients without neurological symptoms. 81% of patients, on the other hand, displayed neurological evidence of anti-APL antibodies. SLE may be generalized or incomplete, with the exception of the epileptic state.

Aseptic meningitis, myelopathy, optic neuropathy, or other desensitizing disorders may require an urgent assessment. An uncommon, but severe, disorder of spastic para paresis is transverse myelitis from SLE. In order to list different manifestations, the CNS nomenclature for lupus has been revised. Cognitive disorder can take several forms in patients suffering from SLE. In 21 to 67 percent of SLE patients, systemic neuropsychiatric examination shows deficits. If this constitutes real encephalopathy, brain damage, aftercare, addiction, or any other cause is not understood (D'Cruz et al., 2007).

Manifestations from the lungs

The signs of acute or viscous SLE can be seen in the lungs, suggesting different complications. Serositis can affect the heart and the pulmonary system, often arising at the same time as serositis of the heart and lungs. The most severe characteristic of acute pulmonary disease in SLE is pleurisy and pleuritic chest pain, with or without pleural effusion. The shortness of breath or shortness of breath may be blamed for different variables. Based on pericardial or pulmonary embolism, pulmonary embolism, lupus pneumonia, chronic interstitial lupus lung disease, full pulmonary leucoaggregation or inflammation, lupus diagnosis can be synonymous with serositis (Derksen & # 38; Meilof, 1992).

Events of the Gastrointestinal

A typical characteristic of SLE is lip ulceration. Oral ulceration is actually one of the eleven parameters used for the identification of SLE by the American College of Rheumatology. SLE reactions and drug lesions, which are normal in persons with SLE, are a significant consequence of gastrointestinal symptoms. Abdominal pain in SLE lupus is extreme and active, including peritonitis, pancreatitis, mesenteric vasculitis, and intestinal infarction that are strongly linked. Weakness and dyspepsia are persistent conditions of individuals with active SLE, and frequently can not be associated with objective proof of gastrointestinal involvement. There may also be jaundice caused by autoimmune hepatitis. In patients with SLE, gastrointestinal issues are normal and can be associated with primary gastrointestinal conditions, medical problems, or SLE itself (Izmirly et al., 2012).

CONCLUSION

Systemic lupus erythematosus, a multifaceted occurrence, is a chronic inflammatory connective tissue disease. Systemic lupus erythematosus is a systemic immune-mediated disease associated with a number of defects in the skin, kidney, hematology, and musculoskeletal. It is not clear about the general symptoms. Arthralgia and arthritis, malaria and other rashes, pleurisy or pericarditis, involvement of the kidney or CNS, and hematological cytopenia are common symptoms. SLE is a protein in its manifestations, and it takes a path of relapse and remission. The seriousness of the disease is wide, since

SLE can cause severe problems due to increased organ damage, coagulation disorders. SLE is characterized by a response to nuclear and cytoplasmic antigens by an autoantibody. As a result of organ involvement, it can be lethal.

Pathogenic mechanisms leading to the clinical lupus phenotype are apparent, with genetic predisposition arising from the induction of the innate immune system in combination with the abnormal collaboration of the tuberculosis cell and the consequent inflammation and damage to the tissues caused by environmental and/or inflammatory factors. Stochastic, stasis. It is important to take these interactions into account and, as clinical trials have demonstrated in patients, from a treatment context, their disorder is important.

REFERENCES

- Alexander, E., Buyon, J. P., Provost, T. T., & Guarnieri, T. Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, An Experimental Model. *Arthritis & Rheumatism*, 1992; 35(2): 176–189. <https://doi.org/10.1002/art.1780350209>
- Anti-Ro (SS-A)/La(SS-B) antibodies in the pathophysiology of congenital heart block (CHB) in neonatal lupus erythematosus (NLE). *Journal of Autoimmunity*, 1989; 2(4): 591–592. [https://doi.org/10.1016/0896-8411\(89\)90210-2](https://doi.org/10.1016/0896-8411(89)90210-2)
- Cervera, R., Khamashta, M., & Hughes, G. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. *Lupus*, 2009; 18(10): 869–874. <https://doi.org/10.1177/0961203309106831>
- Choi, J., Kim, S. T., & Craft, J. The pathogenesis of systemic lupus erythematosus—an update. *Current Opinion in Immunology*, 2012; 24(6): 651–657. <https://doi.org/10.1016/j.coi.2012.10.004>
- Cojocaru, M., Cojocaru, I. M., Silosi, I., & Vrabie, C. D. Manifestations of systemic lupus erythematosus. *Maedica*, 2011; 6(4): 330–336. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391953/>
- D’Cruz, D. P., Khamashta, M. A., & Hughes, G. R. Systemic lupus erythematosus. *The Lancet*, 2007; 369(9561): 587–596. [https://doi.org/10.1016/s0140-6736\(07\)60279-7](https://doi.org/10.1016/s0140-6736(07)60279-7)
- Derksen, R. H. W. M., & Meilof, J. F. Anti-Ro/SS-A and Anti-La/SS-B autoantibody levels in relation to systemic lupus erythematosus disease activity and congenital heart block. *Arthritis & Rheumatism*, 1992; 35(8): 953–959. <https://doi.org/10.1002/art.1780350817>
- Dhaher, Y., Khamashta, M., Hartley, B., Taub, N., Farine, J., & Hughes, G. The effect of OM-89 (SUBREUM®) on the murine model of systemic lupus erythematosus MRL-lpr/lpr. *Lupus*, 1997; 6(5): 436–440. <https://doi.org/10.1177/096120339700600504>
- Izmirly, P. M., Buyon, J. P., & Saxena, A. Neonatal lupus. *Current Opinion in Rheumatology*, 2012; 24(5): 466–472. <https://doi.org/10.1097/bor.0b013e328356226b>
- Lee, L. A. Neonatal lupus erythematosus. *The Journal of Investigative Dermatology*, 1993; 100(1): 9–13. <https://doi.org/10.1111/1523-1747.ep12355173>
- Lee, Lela A. Maternal autoantibodies and pregnancy—II: The neonatal lupus syndrome. *Baillière’s Clinical Rheumatology*, 1990; 4(1): 69–84. [https://doi.org/10.1016/s0950-3579\(05\)80244-4](https://doi.org/10.1016/s0950-3579(05)80244-4)
- Lee, Lela A. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. *Autoimmunity Reviews*, 2005; 4(4): 207–213. <https://doi.org/10.1016/j.autrev.2004.11.003>
- Nakamura, N., Yamabe, H., & Okumura, K. Change in blood group in systemic lupus erythematosus – Authors’ reply. *The Lancet*, 2007; 369(9557): 187. [https://doi.org/10.1016/s0140-6736\(07\)60100-7](https://doi.org/10.1016/s0140-6736(07)60100-7)
- Neonatal Lupus Erythematosus: Clinical Findings and Pathogenesis. *Journal of Investigative Dermatology Symposium Proceedings*, 2004; 9(1): 52–56. <https://doi.org/10.1111/j.1087-0024.2004.00827.x>
- UpToDate. (n.d.). *Www.Uptodate.com*. Retrieved, 2021; 19. from https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-systemic-lupus-erythematosus-in-adults?search=overview-of-the-clinical-manifestations-of-systemic-lupus-erythematosus-in-adults&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1